Disc Medicine (IRON) Stock Price, News & Analysis

Company Overview

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins.

Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.

Key Stats

• Today's Range: $59.37 to $61.04
• 50-Day Range: $52.97 to $61.91
• 52-Week Range: $30.82 to $68.73
• Volume: 178,558 shs
• Average Volume: 279,542 shs
• Market Capitalization: $2.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $98.30
• Consensus Rating: Buy

Disc Medicine Stock Analysis - MarketRank™

Disc Medicine scored higher than 65% of companies evaluated by MarketBeat, and ranked 376th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Disc Medicine has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Disc Medicine has a consensus price target of $98.30, representing about 64.3% upside from its current price of $59.82.

Amount of Analyst Coverage

Disc Medicine has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Disc Medicine is -13.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Disc Medicine is -13.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Disc Medicine has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.15% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Disc Medicine has recently decreased by 13.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Disc Medicine does not currently pay a dividend.

Dividend Growth

Disc Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.15% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Disc Medicine has recently decreased by 13.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.71

News Sentiment

Disc Medicine has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Disc Medicine this week, compared to 6 articles on an average week.

Search Interest

Only 7 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,856,571.00 in company stock.

Percentage Held by Insiders

Only 3.64% of the stock of Disc Medicine is held by insiders.

Percentage Held by Institutions

83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRON Stock Analysis - Frequently Asked Questions

How have IRON shares performed this year?

Disc Medicine's stock was trading at $63.40 on January 1st, 2025. Since then, IRON stock has decreased by 5.6% and is now trading at $59.82.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) released its quarterly earnings results on Thursday, August, 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by $0.41.

Who are Disc Medicine's major shareholders?

Top institutional investors of Disc Medicine include Frazier Life Sciences Management L.P. (4.78%), JPMorgan Chase & Co. (2.44%), Geode Capital Management LLC (1.73%) and Bain Capital Life Sciences Investors LLC (1.68%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Kevin Bitterman, Mona Ashiya, John D Quisel, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Brian Richard Macdonald, Joanne Bryce and William Richard White.
View institutional ownership trends.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Disc Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IRON
• CIK: 1816736
• Web: www.discmedicine.com
• Phone: 617-401-4400
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Disc Medicine: $98.30
• High Price Target: $132.00
• Low Price Target: $75.00
• Potential Upside/Downside: +64.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.60%
• Return on Assets: -24.58%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 32.11
• Quick Ratio: 32.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.85 per share
• Price / Book: 4.03

Miscellaneous

• Outstanding Shares: 34,770,000
• Free Float: 33,501,000
• Market Cap: $2.08 billion
• Optionable: Not Optionable
• Beta: 0.77